Jahanshahi Moghadaseh, Aleyasin Ashraf, Aghahosseini Marzieh, Najafian Aida, Shabani Nashtaei Maryam, Hosseinimousa Sedigheh
Clinical Research Developmental Center (CRDC), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran.
Department of Obstetrics and Gynecology, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ann Med Surg (Lond). 2022 Jun 25;79:104091. doi: 10.1016/j.amsu.2022.104091. eCollection 2022 Jul.
HCG (human chorionic gonadotropin), which is secreted by cytotrophoblast cells, plays an important role in improving pregnancy outcomes among patients with infertility or related problems. In this study, we evaluate the effect of intrauterine hCG injection prior to frozen embryo transfer on pregnancy outcomes.
In this clinical trial study, among women with infertility problems referred to (XXX) and those with frozen embryos were included in the study. 155 patients in the intervention group received 500 units of hCG while 157 in control group received saline prior to embryo transfer. Along with demographic data, successful in vitro fertilization and clinical pregnancy, loss of pregnancy, successful transplantation, and biochemical parameters were compared among the two groups.
The mean age of the patients included in the study was 32.97 ± 3.31 years. The level of anti-Mullerian hormone, follicle stimulating hormone and the grade of frozen embryos were not significantly different between the two groups (P > 0.05). The rate of laboratory pregnancy in the intervention group was significantly higher than in the control group (51% vs 35%), p = 0.006. The rate of successful implantation and clinical pregnancy in the intervention group was also significantly higher, p = 0.01 and p = 0.006, respectively. Overall loss of pregnancy in intervention group was 78.1% and 86.0% in control group which was not significantly different, p = 0.068.
The outcomes of our study showed that 500 IU of hCG prior to embryo transfer improves the rate of clinical and laboratory pregnancy. However, it does not reduce the rate of loss of pregnancy. Further studies are therefore required in this area.
人绒毛膜促性腺激素（HCG）由细胞滋养层细胞分泌，在改善不孕或相关问题患者的妊娠结局中发挥重要作用。在本研究中，我们评估了冻融胚胎移植前宫腔内注射HCG对妊娠结局的影响。
在这项临床试验研究中，纳入了转诊至（XXX）的不孕问题女性及有冻融胚胎的女性。干预组155例患者在胚胎移植前接受500单位HCG，而对照组157例患者接受生理盐水。比较两组的人口统计学数据、体外受精成功情况、临床妊娠、妊娠丢失、移植成功情况及生化指标。
纳入研究的患者平均年龄为32.97±3.31岁。两组间抗苗勒管激素水平、促卵泡生成素水平及冻融胚胎等级无显著差异（P>0.05）。干预组的实验室妊娠率显著高于对照组（51%对35%），P=0.006。干预组的成功着床率和临床妊娠率也显著更高，P分别为0.01和0.006。干预组的总体妊娠丢失率为78.1%，对照组为86.0%，无显著差异，P=0.068。
我们的研究结果表明，胚胎移植前注射500IU HCG可提高临床妊娠率和实验室妊娠率。然而，它并未降低妊娠丢失率。因此，该领域需要进一步研究。
